AACR Announces 2025 Scientific Achievement Award Recipients
Awardees to be recognized at the AACR Annual Meeting 2025 in Chicago CHICAGO – The American Association for Cancer...
Search/Filter
Loading...
AACR Announces Recipients of the 2025 AACR June L. Biedler Prize for Cancer Journalism
PHILADELPHIA – The American Association for Cancer Research (AACR) is pleased to announce the recipients of the 2025 AACR...
Rakesh K. Jain, PhD, FAACR, Honored with the 2025 AACR Award for Lifetime Achievement in Cancer Research
CHICAGO – The 2025 AACR Award for Lifetime Achievement in Cancer Research will be presented to Rakesh K. Jain,...
Douglas Hanahan, PhD, FAACR, Honored with the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
CHICAGO – The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will...
AACR Announces Fellows of the AACR Academy Class of 2025 and New AACR Academy President
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of...
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane- based Chemotherapy
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not...
Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they...